SCHEMBL2897750

SCHEMBL2897750

COC(=O)c1cc(N)c(C(=O)OC)cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.61
ALDH1A1 P00352 6/20 0.59
GAA P10253 5/20 0.59
HSD17B10 Q99714 3/20 0.59
HPGD P15428 3/20 0.59
MAPT P10636 3/20 0.59
GLA P06280 2/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
ATM Q13315 1/20 0.59
ABL1 P00519 1/20 0.53
TSHR P16473 2/20 0.51
ALOX15 P16050 1/20 0.51
CFTR P13569 5/20 0.50
POLB P06746 1/20 0.43
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42
PDGFRA P16234 1/20 0.42
FLT1 P17948 1/20 0.42
FGFR3 P22607 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2427397 0.91 KDM4E (0.54) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL681252 0.90 KDM4E (0.63) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL1720999 0.90 KDM4E (0.56) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL4758833 0.89 KDM4E (0.73) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL30280995 0.88 KDM4E (0.55) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL2318882 0.88 KDM4E (0.55) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL274700 0.88 KDM4E (0.55) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL2430255 0.87 KDM4E (0.50) KDM4EALDH1A1GAAHSD17B10HPGD
Hydrochloric Acid SCHEMBL5417457 0.86 KDM4E (0.53) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL27501597 0.86 KDM4E (0.59) KDM4EALDH1A1GAAHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 EP disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 KDM4E 206/4885ALDH1A1 204/4885GAA 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.